Skip to main
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 36%
Hold 36%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is a dominant player in the genomics market, with a focus on providing tools and services for genetic analysis in both clinical and academic settings. Despite some recent challenges with instrument mix and competition, the company remains poised for sustained growth in the clinical market and has a strong pipeline of products in development. The recent acceleration in clinical growth shows potential for long-term success and the company's strategic investments in areas like BioInsight and the SomaLogic acquisition demonstrate its commitment to continued expansion. While there are risks to consider, including ongoing uncertainties in China and potential competition, the overall outlook for Illumina is positive and the company is well-positioned for continued growth in the long term.

Bears say

Illumina is a leading provider of genetic analysis tools and services, but the company's reliance on high-throughput sequencing instruments and consumables puts it at risk of facing competitive pressure and potential pricing pressures. Customers typically place multi-quarter orders in advance, providing good short-term visibility, but there are concerns about shelf life and stocking dynamics. Additionally, while the company has experienced strong growth in clinical markets, sustained growth at this rate may be difficult to maintain and academic weakness is an industry-wide problem. Overall, the company's valuation is reasonable but its earnings are burdened by past overbuild, and any further weakness in demand could impact performance.

Illumina (ILMN) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 36% recommend Buy, 36% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Hold based on their latest research and market trends.

According to 14 analysts, Illumina (ILMN) has a Hold consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $189.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $189.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.